First patient treated on Mevion’s S250i proton therapy system

By News Release
0  Votes

Mevion Medical Systems has announced that the first patient has received treatment with the MEVION S250i Proton Therapy System at MedStar Georgetown University Hospital in Washington, D.C.

“The launch of the HYPERSCAN system is a major milestone in the field of proton therapy. It is the realization of a vision to create the most clinically advanced and economically viable proton therapy system in the world making proton therapy accessible across the spectrum of healthcare providers,” said Joseph Jachinowski, CEO of Mevion Medical Systems, in a company release. “Mevion has consistently pushed the field of proton therapy forward. We first changed proton therapy by introducing a new paradigm of economic, compact proton systems and now we are doing it again by deploying an advanced approach to pencil beam delivery. These achievements are the result of a team passionate about the impact proton therapy can have on patients’ lives.”

New Clinical Capabilities

Proton therapy is a precise form of radiation therapy that has the potential to reduce the amount of radiation exposure in some cancers. The Mevion system at MedStar Georgetown includes HYPERSCAN pencil beam scanning (PBS), which improves existing proton scanning capabilities, enabling clinicians to deliver conformal fields faster and with more precision than in the past.

The HYPERSCAN system uses a novel technology, the Adaptive Aperture, a proton multileaf collimator (pMLC), to achieve sharp lateral dose gradients. Multileaf collimators are common to conventional radiation therapy and were a key enabling technology to make intensity modulated radiation therapy (IMRT) possible. Mevion’s Adaptive Aperture pMLC is unique to proton therapy. Designed to protect sensitive organs at every energy layer of the treatment, this new type of proton MLC enables a similar paradigm change in proton therapy.

Uptick in Global Adoption

In addition to MedStar Georgetown, the MEVION S250i system is under active installation at centers throughout the US and Europe. Two more HYPERSCAN centers will be treating patients by the end of 2018. An additional two centers are in the construction planning phase, both of which are instances of existing sites adding a second treatment room.

“We are excited to see the rapid adoption of Mevion’s HYPERSCAN technology,” said Yoel Bakas, senior vice president of sales for Mevion Medical Systems. “Proton therapy has long been viewed as economically unrealistic for most cancer centers. The uptick in proton projects and repeat customers speaks to the strength of the Mevion economic and clinical approach.”

Integration and Economics in Proton Therapy

At Medstar Georgetown, the proton system is integrated directly to the hospital as part of a renovation to the existing cancer center entrance. While other proton centers often have to be built as separate standalone facilities, the compact size of the Mevion system enables it to be integrated to existing radiation oncology departments. This can bring significant economic savings to these projects by enabling the centers to share existing support services and personnel throughout the hospital rather than duplicating them in a standalone facility.

Proton Therapy Symposium at ESTRO 37

Mevion will be hosting a luncheon symposium at the annual European Society for Radiotherapy & Oncology (ESTRO) in Barcelona Spain on Saturday April 21st. Attendees are invited to learn more about HYPERSCAN pencil beam scanning and compact Mevion proton therapy systems. A panel of speakers will be discussing the implementation of these projects and the clinical experiences of the HYPERSCAN system.

Back To Top

First patient treated on Mevion’s S250i proton therapy system.  Appl Rad Oncol. 

By News Release| April 03, 2018
Categories:  Section|Technologies

About the Author

News Release

News Release

 



Copyright © Anderson Publishing, Ltd

 2018
    Agility CMS